JP4757493B2 - 抗原ｐｉｐａおよびそれに結合する抗体 - Google Patents

抗原ｐｉｐａおよびそれに結合する抗体 Download PDF

Info

Publication number
JP4757493B2
JP4757493B2 JP2004552160A JP2004552160A JP4757493B2 JP 4757493 B2 JP4757493 B2 JP 4757493B2 JP 2004552160 A JP2004552160 A JP 2004552160A JP 2004552160 A JP2004552160 A JP 2004552160A JP 4757493 B2 JP4757493 B2 JP 4757493B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
pipa
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004552160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006506071A5 (https=
JP2006506071A (ja
Inventor
ジェニー ピー． マーサー，
ロングハオ リ，
トーニー ダブリュー． リアン，
Original Assignee
レイベン バイオテクノロジーズ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイベン バイオテクノロジーズ，インコーポレイティド filed Critical レイベン バイオテクノロジーズ，インコーポレイティド
Publication of JP2006506071A publication Critical patent/JP2006506071A/ja
Publication of JP2006506071A5 publication Critical patent/JP2006506071A5/ja
Application granted granted Critical
Publication of JP4757493B2 publication Critical patent/JP4757493B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004552160A 2002-11-13 2003-11-13 抗原ｐｉｐａおよびそれに結合する抗体 Expired - Fee Related JP4757493B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42619202P 2002-11-13 2002-11-13
US60/426,192 2002-11-13
PCT/US2003/036134 WO2004043239A2 (en) 2002-11-13 2003-11-13 Antigen pipa and antibodies that bind thereto

Publications (3)

Publication Number Publication Date
JP2006506071A JP2006506071A (ja) 2006-02-23
JP2006506071A5 JP2006506071A5 (https=) 2007-01-11
JP4757493B2 true JP4757493B2 (ja) 2011-08-24

Family

ID=32313118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552160A Expired - Fee Related JP4757493B2 (ja) 2002-11-13 2003-11-13 抗原ｐｉｐａおよびそれに結合する抗体

Country Status (6)

Country Link
US (1) US7405061B2 (https=)
EP (1) EP1581096A4 (https=)
JP (1) JP4757493B2 (https=)
AU (1) AU2003295474B2 (https=)
CA (1) CA2505633A1 (https=)
WO (1) WO2004043239A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004043239A2 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
ES2900801T3 (es) 2004-12-22 2022-03-18 Nitto Denko Corp Portador de fármacos y kit de portador de fármacos para inhibir la fibrosis
AU2006210589B2 (en) 2005-02-02 2011-12-08 Macrogenics West, Inc. ADAM-9 modulators
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
TWI407971B (zh) 2007-03-30 2013-09-11 日東電工股份有限公司 Cancer cells and tumor-related fibroblasts
EP2376109B1 (en) 2008-12-19 2019-01-23 MacroGenics, Inc. Covalent diabodies and uses thereof
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
EP2601216B1 (en) 2010-08-02 2018-01-03 MacroGenics, Inc. Covalent diabodies and uses thereof
CA2836873C (en) 2011-05-21 2019-10-22 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
RU2639459C2 (ru) 2011-06-21 2017-12-21 Нитто Денко Корпорейшн Апоптоз-индуцирующее средство
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
JP6076076B2 (ja) 2012-12-21 2017-02-08 日東電工株式会社 組織再生促進剤
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
JP6727765B2 (ja) 2014-06-17 2020-07-22 日東電工株式会社 アポトーシス誘導剤
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) * 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5496550A (en) * 1986-08-14 1996-03-05 Chilwalner Method of reducing the output of Eimeria oocysts from a newborn chick
EP0299242A3 (en) * 1987-06-22 1989-01-25 Medico Labs Ag Heterologous viral peptide particle immunogens
US5677425A (en) * 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) * 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) * 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) * 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
ES2136092T3 (es) * 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) * 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
DE69333627T2 (de) * 1993-01-14 2005-09-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Rekombinanter anti-hiv antikörper und seine herstellung
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5665570A (en) * 1994-02-10 1997-09-09 Takeda Chemical Industries, Ltd. Antibody-encoding recombinant DNA and its use
US5532159A (en) * 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2077197A (en) * 1996-03-18 1997-10-10 Novo Nordisk Biotech, Inc. Polypeptides having phytase activity and nucleic acids encoding same
CA2249998A1 (en) * 1996-03-27 1997-10-02 Crc For Biopharmaceutical Research Pty. Ltd. The use of antibodies against cd48 for the treatment of t and b cell lymphomas and leukemias
ID20581A (id) 1996-10-18 1999-01-21 Res Fnd For Micbial Diseases O Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
DE29803477U1 (de) * 1998-03-03 1998-07-09 P.E.R. Flucht- und Rettungsleitsysteme GmbH, 22885 Barsbüttel Vorrichtung zur Ausbildung aktiv leuchtender Leuchtwegesysteme
US6406840B1 (en) * 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6416999B1 (en) * 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6441163B1 (en) * 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
WO2004043239A2 (en) 2002-11-13 2004-05-27 Raven Biotechnologies, Inc. Antigen pipa and antibodies that bind thereto

Also Published As

Publication number Publication date
AU2003295474B2 (en) 2009-07-30
WO2004043239A2 (en) 2004-05-27
JP2006506071A (ja) 2006-02-23
US7405061B2 (en) 2008-07-29
WO2004043239A3 (en) 2005-09-29
EP1581096A2 (en) 2005-10-05
EP1581096A4 (en) 2006-06-21
AU2003295474A1 (en) 2004-06-03
US20040171814A1 (en) 2004-09-02
CA2505633A1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
JP5601836B2 (ja) Ｔｅｓ７およびｔｅｓ７に結合する抗体
JP4757493B2 (ja) 抗原ｐｉｐａおよびそれに結合する抗体
US8361475B2 (en) ADAM-9 modulators
JP4621674B2 (ja) Ｋｉｄ３およびｋｉｄ３に結合するｋｉｄ３抗体
US8313916B2 (en) KID31 and antibodies that bind thereto
JP5328156B2 (ja) オンコスタチンｍレセプターに対する抗体
US20110045006A1 (en) LUCA2 and Antibodies That Bind Thereto
JP2011130770A (ja) 新規のｒａａｇ１０細胞表面標的および当該標的を認識する抗体ファミリー
US20060171952A1 (en) JAM-3 and antibodies that bind thereto
JP2006506071A5 (https=)
HK1107402B (en) Kid31 and antibodies that bind thereto

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20061108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100302

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100402

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100409

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101014

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101021

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110421

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110511

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110601

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140610

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140610

Year of fee payment: 3

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140610

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D14

LAPS Cancellation because of no payment of annual fees